The combination of melphalan and prednisone has been accepted as standard treatment for multiple myeloma (MM) because most studies demonstrate only minimal survival benefit of combination chemotherapy regimens when compared with melphalan and prednisone. Despite modest gains with more intensive myeloablative regimens for certain subgroups, myeloma remains incurable. In 1999, investigators at the University of Arkansas reported the promising results of a phase II study of thalidomide in patients with resistant MM. Since then various trials of thalidomide alone, and in combination, have been tested in patients with resistant, and more recently, untreated MM. In addition, preliminary results of phase I studies of the immunomodulatory derivatives (IMiDs) of thalidomide have recently been reported.
Methods
The author reviewed and reports the results of clinical trials of thalidomide and the IMiDs, as well as the pharmacology, mechanism of action, and toxicity of these agents.
Results
Thalidomide has demonstrated significant activity in both resistant and previously untreated multiple myeloma. Combination therapy with dexamethasone increases response rate, even in patients previously resistant to both drugs given as single agents, indicating probable synergy. More recent studies of thalidomide-dexamethasone in previously untreated patients are encouraging. IMiD-3 is active in resistant myeloma and has a toxicity profile different from that of thalidomide.
Conclusions
Many studies have confirmed the activity of thalidomide in MM, as well as more responses with dexamethasone. Newer thalidomide derivatives with reduced toxicity are promising. Thalidomide-dexamethasone may now represent the treatment of choice for previously untreated patients. Further studies with these and other novel agents early in the course of myeloma, followed by rational programs of dose intensification, may improve complete remission rates and the frequency of long-term control.
References
1.
JamalA., MurrayT., SamuelsA.. Cancer statistics, 2003.CA Cancer J Clin.2003; 53: 5–26.
2.
Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials.Myeloma Trialist's Collaborative Group.J Clin Oncol.1998; 16: 3832–3842.
3.
BarlogieB., SmithL., AlexanianR.. Effective treatment of advanced multiple myeloma refractory to alkylating agents.N Engl J Med.1984; 310: 1353–1356.
4.
D'AmatoR.J., LoughranM.S., FlynnE.. Thalidomide is an inhibitor of angiogenesis.Proc Natl Acad Sci U S A.1994; 91: 4082–4085.
5.
VaccaA., RibattiD., RoncaliL.. Bone marrow angiogenesis and progression in multiple myeloma.Br J Haematol.1994; 87: 503–508.
6.
MunshiN., WilsonC.S.. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis.Semin Oncol.2001; 28: 565–569.
7.
SinghalS., MehtaJ., DesikanR.. Antitumor activity of thalidomide in refractory multiple myeloma.N Engl J Med.1999; 341: 1565–1571.
8.
LenzW.. Thalidomide and congenital anomalies.Lancet.1962; 1: 45.
9.
TsengS., PakG., WashenikK.. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses.J Am Acad Dermatol.1996; 35: 969–979.
10.
StirlingD.I.. Pharmacology of thalidomide.Semin Hematol.2000, 37(1 suppl 3): 5–14.
11.
RichardsonP., HideshimaT., AndersonK.. Thalidomide: emerging role in cancer medicine.Annu Rev Med.2002; 53: 629–657.
12.
ChenT.L., VogelsangG.B., PettyB.G.. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.Drug Metab Dispos.1989; 17: 402–405.
13.
KenyonB.M., BrowneF., D'AmatoR.. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization.Exp Eye Res.1997; 64: 971–978.
TurkB.E., JiangH., LiuJ.O.. Binding of thalidomide to alpha 1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor alpha production.Proc Natl Acad Sci U S A.1996; 93: 7552–7556.
16.
VaccaA., RibattiD., PrestaM.. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2-secretion parallel progression of human multiple myeloma.Blood.1999; 93: 3064–3073.
17.
BellamyW., RichterL., FrutigerY.. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies.Cancer Res.1999; 59: 728–733.
18.
MitsiadesN., MitsiadesC.S., PoulakiV.. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.Blood.2002; 99: 4525–4530.
19.
WitzigT.E.. The role of adhesion receptors in the pathogenesis of multiple myeloma.Hematol Oncol Clin North Am.1999; 13: 1127–1143.
20.
SampaioE.P., SarnoE.N., GalillyR.. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes.J Exp Med.1991; 173: 699–703.
21.
DaviesF.E., RajeN., HideshimaT.. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood.2001; 98: 210–216.
22.
HideshimaT., ChauhanD., ShimaY.. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood.2000; 96: 2943–2950.
23.
BarlogieB., DesikanR., EddelmonP.. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients.Blood.2001; 98: 492–494.
24.
WeberD.M., RankinK., GavinoM.. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.J Clin Oncol.2003; 21: 16–19.
25.
AlexanianR., WeberD.. Thalidomide for resistant and relapsing myeloma.Semin Hematol.2000; 37(1 suppl 3): 22–25.
26.
DurieB.G.M., StepanD.E.. Efficacy of low dose thalidomide (T) in multiple myeloma.Blood.1999; 94(suppl 1): 316. Abstract.
27.
ColemanM., LeonardJ.P., NahumK.. Non-myelosuppressive therapy with BLT-D ([Biaxin], low-dose thalidomide, and dexamethasone) is highly active in Waldenström's macroglobulinemia and myeloma.Blood.2000; 96: 167. Abstract.
28.
ZeldisJ.B., WilliamsB.A., ThomasS.D.. S.T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide.Clin Ther.1999; 21: 319–330.
OsmanK., ComenzoR., RajkumarS.V.. Deep venous thrombosis and thalidomide therapy for multiple myeloma.N Engl J Med.2001; 25: 1951–1952.
31.
ZangariM., SiegelE., BarlogieB.. Thrombogenic activity of doxorubicin in myeloma patients receiving thalidomide: implications for therapy.Blood.2002; 100: 1168–1171.
32.
JuliussonG., CelsingF., TuressonI.. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.Br J Haematol.2000; 109: 89–96.
33.
Yakoub-AghaI., AttalM., DumontetC.. Thalidomide in patients with advanced multiple myeloma: a study of 83 patients. Report of the Intergroupe Francophone du Myelome (IFM).Hematol J.2002; 3: 185–192.
34.
RazaS.N., VekslerY., SabirT.. Durable response to thalidomide in relapsed/refractory multiple myeloma.Blood.2000; 96: 168. Abstract.
35.
RajkumarS.V., FonsecaR., DispenzieriA.. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma with laboratory correlative studies.Blood.2000; 96: 168. Abstract.
36.
TosiP., RonconiS., ZamagniE.. Salvage therapy with thalidomide for patients with advanced relapsed/refractory multiple myeloma.Blood.2000; 96: 296. Abstract.
37.
GrosboisB., BellissantE., MoreauP.. Thalidomide (Thal) in the treatment of advanced multiple myeloma (MM): a prospective study of 120 patients.Blood.2001: 98(pt 1): 689. Abstract.
38.
HusM., DMoszynskaA., Soroka-WojtaszkoM.. Thalidomide treatment of resistant or relapsed multiple myeloma patients.Haematologica.2001; 86: 404–408.
39.
WeberD.M., RankinK., DelasalleK.. Thalidomide alone and in combination of previously untreated myeloma. Program and abstracts of the VIII International Myeloma Workshop, May 4-8, 2001, Banff, Alberta, Canada. Abstract S66.
40.
DimopoulosM.A., ZervasK., KouvatseasG.. Thalidomide and dexamethasone combination for refractory multiple myeloma.Ann Oncol.2001; 12: 991–995.
41.
PalumboA., GiacconeL., BertolaA.. Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma.Haematologica.2001; 86: 399–403.
42.
TosiP., ZamagniE., CelliniC.. Rapid response and early relapse after thalidomide plus dexamethasone salvage therapy in patients with advanced and refractory multiple myeloma.Blood.2001; 98: 687. Abstract.
43.
KropffM.H., InnigG., MittererM.. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (Hyper-CDT) in primary refractory or relapsed multiple myeloma.Blood.2000; 96: 725. Abstract.
44.
MoehlerT.M., NebenK., BennerA.. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy.Blood.2001; 98: 3846–3848.
45.
BarlogieB., ZangariM., SpencerT.. Thalidomide in the management of multiple myeloma.Semin Hematol.2001; 38: 250–259.
46.
WeberD.M., RankinK., GavinoM.. Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.J Clin Oncol.2003; 21: 16–19.
47.
RajkumarS.V., HaymanS., FonsecaR.. Thalidomide plus dexamethasone (Thal/dex) and thalidomide alone (Thal) as first line therapy for newly diagnosed myeloma (MM).Blood.2000; 96: 168. Abstract.
48.
RajkumarS.V., DispenzieriA., FonsecaR.. Thalidomide for previously untreated indolent or smoldering multiple myeloma.Leukemia.2001; 15: 1274–1276.
49.
RajkumarS.V., HaymanS.R., GertzM.A.. Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.J Clin Oncol.2002; 20: 4319–4323.
50.
AlexanianR., WeberD., GiraltS.. Impact of complete remission with intensive therapy in patients with responsive multiple myeloma.Bone Marrow Transplant.2001; 27: 1037–1043.
51.
AlexanianR., WeberD., GiraltS.. Consolidation therapy of multiple myeloma with thalidomide-dexamethasone after intensive chemotherapy.Ann Oncol.2002; 13: 1116–1119.
52.
BladeJ., PeralesM., RosinolL.. Thalidomide in multiple myeloma: lack of response of soft tissue plasmacytomas.Br J Haematol.2001; 113: 422–424.
53.
MyersB., GrimleyC., CrouchD.. Lack of response to thalidomide in plasmacytomas.Br J Haematol.2001; 115–234.
54.
RichardsonP.G., SchlossmanR.L., HideshimaT.. A phase I study of oral CC5013, an Immunomodulatory thalidomide (thal) derivative, in patients with relapsed and refractory multiple myeloma (MM).Blood.2001; 3225. Abstract.
55.
ZangariM., TricotG., ZeldisJ.. Results of a phase I study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT).Blood.2001; 3226. Abstract.
